SLC35F2

Summary

SLC35F2 (solute carrier family 35 member F2, HGNC:23615) is a protein-coding gene on chromosome 11q22.3, encoding Queuine/queuosine transporter SLC35F2 (Q8IXU6). High affinity plasma membrane importer of the nucleobase queuine (q) and its nucleoside queuosine (Q), two bacterially derived micronutrients acquired from the gut microbiome and diet.

Predicted to enable transmembrane transporter activity. Predicted to be involved in transmembrane transport. Predicted to be located in membrane.

Source: NCBI Gene 54733 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 57 total
• MANE Select transcript: NM_017515

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23615
Approved symbol	SLC35F2
Name	solute carrier family 35 member F2
Location	11q22.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ13018
Ensembl gene	ENSG00000110660
Ensembl biotype	protein_coding
OMIM	620350
Entrez	54733

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 7 protein_coding, 3 nonsense_mediated_decay

ENST00000375682, ENST00000524991, ENST00000525071, ENST00000525815, ENST00000532513, ENST00000533664, ENST00000869080, ENST00000869081, ENST00000914205, ENST00000956832

RefSeq mRNA: 1 — MANE Select: NM_017515 NM_017515

CCDS: CCDS41709

Canonical transcript exons

ENST00000525815 — 8 exons

Exon	Start	End
ENSE00002181537	107790991	107792800
ENSE00002181976	107858658	107858787
ENSE00003485349	107806717	107806876
ENSE00003491486	107805359	107805515
ENSE00003575261	107811667	107811794
ENSE00003588068	107803001	107803155
ENSE00003592967	107815790	107815965
ENSE00003638178	107804718	107804770

Expression profiles

Bgee: expression breadth ubiquitous, 225 present calls, max score 92.45.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 17.2917 / max 433.7576, expressed in 1730 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
122131	9.1481	1627
122129	3.8820	1194
122136	1.9484	851
122132	1.2474	802
122133	0.6110	335
122130	0.2112	99
122134	0.1152	28
122137	0.1012	31
122135	0.0272	6

Top tissues by expression

275 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	92.45	gold quality
parotid gland	UBERON:0001831	91.86	gold quality
lower esophagus mucosa	UBERON:0035834	88.74	gold quality
mucosa of transverse colon	UBERON:0004991	88.08	gold quality
rectum	UBERON:0001052	88.04	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	86.93	gold quality
skin of leg	UBERON:0001511	86.66	gold quality
ileal mucosa	UBERON:0000331	86.63	gold quality
skin of abdomen	UBERON:0001416	86.07	gold quality
zone of skin	UBERON:0000014	85.19	gold quality
gingival epithelium	UBERON:0001949	85.18	gold quality
tonsil	UBERON:0002372	84.22	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	83.64	gold quality
gingiva	UBERON:0001828	82.77	gold quality
esophagus mucosa	UBERON:0002469	82.75	gold quality
duodenum	UBERON:0002114	82.46	gold quality
prostate gland	UBERON:0002367	81.99	gold quality
colonic mucosa	UBERON:0000317	81.96	gold quality
oviduct epithelium	UBERON:0004804	81.24	gold quality
transverse colon	UBERON:0001157	80.97	gold quality
jejunal mucosa	UBERON:0000399	80.95	gold quality
saliva-secreting gland	UBERON:0001044	80.84	gold quality
vagina	UBERON:0000996	80.71	gold quality
mucosa of sigmoid colon	UBERON:0004993	80.64	gold quality
ectocervix	UBERON:0012249	80.52	gold quality
fallopian tube	UBERON:0003889	79.66	gold quality
colonic epithelium	UBERON:0000397	79.65	gold quality
thoracic aorta	UBERON:0001515	79.44	gold quality
endocervix	UBERON:0000458	79.43	gold quality
ascending aorta	UBERON:0001496	79.41	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	11.17

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

57 targeting SLC35F2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-8082	99.95	67.27	1170
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-8087	99.90	69.55	1351
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-3140-3P	99.88	68.47	2069
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-5003-3P	99.85	69.29	2517
HSA-MIR-6844	99.82	70.69	2423
HSA-MIR-4307	99.82	70.45	3374
HSA-MIR-3934-3P	99.76	65.51	1351
HSA-MIR-2681-5P	99.75	67.64	1655
HSA-MIR-4766-5P	99.75	69.23	2662
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-425-5P	99.59	67.67	900
HSA-MIR-1915-3P	99.58	66.79	1988
HSA-MIR-582-5P	99.47	70.79	2635
HSA-MIR-578	99.46	68.36	1787

Literature-anchored findings (GeneRIF, showing 6)

• SLC35F2 was highly expressed in NSCLC tissues and the levels of expression, in particular the levels of the SLC35F2 transcript, were associated with NSCLC pathological staging. (PMID:21874247)
• Study showed that SLC35F2 was prominently upregulated in papillary thyroid carcinoma (PTC) tissues at both protein and mRNA expression level and significantly associated with lymph node metastasis. These findings suggest that SLC35F2 exerts its oncogenic effect on PTC progression through the mitogen-activated protein kinase pathway, with dependence on activation of TGFBR-1 and apoptosis signal-regulating kinase 1. (PMID:29274137)
• SLC35F2, a Transporter Sporadically Mutated in the Untranslated Region, Promotes Growth, Migration, and Invasion of Bladder Cancer Cells. (PMID:33418944)
• USP32 confers cancer cell resistance to YM155 via promoting ER-associated degradation of solute carrier protein SLC35F2. (PMID:34815782)
• SLC35F2-SYVN1-TRIM59 axis critically regulates ferroptosis of pancreatic cancer cells by inhibiting endogenous p53. (PMID:37740007)
• betaTrCP1 promotes SLC35F2 protein ubiquitination and inhibits cancer progression in HeLa cells. (PMID:37801987)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	slc35f2	ENSDARG00000069745
danio_rerio	slc35f2l	ENSDARG00000090686
mus_musculus	Slc35f2	ENSMUSG00000042195
rattus_norvegicus	Slc35f2	ENSRNOG00000009014
caenorhabditis_elegans	Y73E7A.3	WBGENE00022270

Paralogs (1): SLC35F1 (ENSG00000196376)

Protein

Protein identifiers

Queuine/queuosine transporter SLC35F2 — Q8IXU6 (reviewed: Q8IXU6)

Alternative names: Solute carrier family 35 member F2

All UniProt accessions (4): Q8IXU6, E9PJD1, E9PKZ2, E9PRY2

UniProt curated annotations — full annotation on UniProt →

Function. High affinity plasma membrane importer of the nucleobase queuine (q) and its nucleoside queuosine (Q), two bacterially derived micronutrients acquired from the gut microbiome and diet. Following cellular uptake, queuosine is incorporated at the wobble base (position 34) of tRNAs that decode histidine, tyrosine, aspartate, and asparagine codons, which is important for efficient translation.

Subcellular location. Cell membrane. Golgi apparatus membrane.

Similarity. Belongs to the SLC35F solute transporter family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q8IXU6-1	1	yes
Q8IXU6-2	2
Q8IXU6-3	3

RefSeq proteins (1): NP_059985* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR009262	SLC35_F1/F2/F6	Family
IPR037185	EmrE-like	Homologous_superfamily
IPR052221	SLC35F_Transporter	Family

Pfam: PF06027

Catalyzed reactions (Rhea), 2 shown:

• queuine(out) = queuine(in) (RHEA:85679)
• queuosine(out) = queuosine(in) (RHEA:85683)

UniProt features (32 total): topological domain 11, transmembrane region 10, modified residue 4, splice variant 3, sequence conflict 3, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8IXU6-F1	82.97	0.54

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 1, 5, 25, 371

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 133 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_UP, MYOGENIN_Q6, chr11q22, GOBP_TRNA_METABOLIC_PROCESS, ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_UP, GOBP_RNA_MODIFICATION, BLALOCK_ALZHEIMERS_DISEASE_UP, DODD_NASOPHARYNGEAL_CARCINOMA_UP, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN, RIGGI_EWING_SARCOMA_PROGENITOR_UP, GOBP_TRANSMEMBRANE_TRANSPORT, GOBP_TRNA_PROCESSING, GOBP_TRNA_MODIFICATION, NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_UP, ZHAN_MULTIPLE_MYELOMA_MS_DN

GO Biological Process (4): tRNA queuosine(34) biosynthetic process from salvaged queuosine or its precursors (GO:0160254), tRNA queuosine(34) biosynthetic process from salvaged queuine (GO:0160255), biological_process (GO:0008150), transmembrane transport (GO:0055085)

GO Molecular Function (2): transmembrane transporter activity (GO:0022857), molecular_function (GO:0003674)

GO Cellular Component (3): plasma membrane (GO:0005886), cellular_component (GO:0005575), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
tRNA queuosine(34) biosynthetic process	2
transport	1
cellular process	1
transporter activity	1
transmembrane transport	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

710 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLC35F2	DOP1B	Q9Y3R5	645
SLC35F2	CSMD1	Q96PZ7	616
SLC35F2	IMMP2L	Q96T52	598
SLC35F2	HNRNPCL1	O60812	583
SLC35F2	CHRFAM7A	Q494W8	574
SLC35F2	ELMOD1	Q8N336	540
SLC35F2	NRXN1	Q9ULB1	494
SLC35F2	RELN	P78509	490
SLC35F2	ERBB4	Q15303	461
SLC35F2	SLC35F3	Q8IY50	459
SLC35F2	RAB39A	Q14964	457
SLC35F2	POGLUT3	Q7Z4H8	446
SLC35F2	SLC35D3	Q5M8T2	432
SLC35F2	BCAR3	O75815	423
SLC35F2	FNBP1L	Q5T0N5	415

IntAct

47 interactions, top by confidence:

A	B	Type	Score
CTBP1	ZEB2	psi-mi:“MI:0914”(association)	0.800
RETREG3	PLSCR1	psi-mi:“MI:0914”(association)	0.640
POMK	LRP5	psi-mi:“MI:0914”(association)	0.640
POMK	TMEM120B	psi-mi:“MI:0914”(association)	0.530
C3AR1	TMEM120B	psi-mi:“MI:0914”(association)	0.530
HTR2C	KLRG2	psi-mi:“MI:0914”(association)	0.530
VSIG1	TNPO2	psi-mi:“MI:0914”(association)	0.530
ATP5PF	SLC19A2	psi-mi:“MI:0914”(association)	0.530
ATP5F1B	SCAMP2	psi-mi:“MI:0914”(association)	0.530
	NBAS	psi-mi:“MI:0914”(association)	0.350
CTBP2	ZEB2	psi-mi:“MI:0914”(association)	0.350
HDAC2		psi-mi:“MI:0914”(association)	0.350
RAB11A	SCAMP1	psi-mi:“MI:0914”(association)	0.350
RAB11B	SCAMP1	psi-mi:“MI:0914”(association)	0.350
SLC35F2	STX7	psi-mi:“MI:0914”(association)	0.350
TTYH1	TMEM223	psi-mi:“MI:0914”(association)	0.350
TSPAN15	TMEM223	psi-mi:“MI:0914”(association)	0.350
BSCL2	TMEM223	psi-mi:“MI:0914”(association)	0.350
CMTM5	TMEM120B	psi-mi:“MI:0914”(association)	0.350
TSPAN31	TMEM120B	psi-mi:“MI:0914”(association)	0.350
TNFRSF10C	SLC22A23	psi-mi:“MI:0914”(association)	0.350
C5AR1	TCAF2	psi-mi:“MI:0914”(association)	0.350
GPR182	METTL15	psi-mi:“MI:0914”(association)	0.350
OPRL1	METTL15	psi-mi:“MI:0914”(association)	0.350
SLC22A4	RTL8C	psi-mi:“MI:0914”(association)	0.350
VIPR2	RABGAP1L	psi-mi:“MI:0914”(association)	0.350
FPR2	GPR89A	psi-mi:“MI:0914”(association)	0.350
KDSR	ACOT7	psi-mi:“MI:0914”(association)	0.350
SLC35F2	STXBP3	psi-mi:“MI:0914”(association)	0.350
KLRC2	CLGN	psi-mi:“MI:0914”(association)	0.350

BioGRID (235): SLC35F2 (Affinity Capture-MS), SLC35F2 (Affinity Capture-MS), SLC35F2 (Proximity Label-MS), SLC35F2 (Affinity Capture-MS), SLC35F2 (Affinity Capture-MS), SLC35F2 (Affinity Capture-MS), SLC35F2 (Affinity Capture-MS), SLC35F2 (Affinity Capture-MS), SLC35F2 (Affinity Capture-MS), SLC35F2 (Affinity Capture-MS), SLC35F2 (Affinity Capture-MS), SLC35F2 (Affinity Capture-MS), SLC35F2 (Affinity Capture-MS), SLC35F2 (Affinity Capture-RNA), SLC35F2 (Affinity Capture-RNA)

ESM2 similar proteins: A0NGI1, A7YW81, O74750, O94654, P40004, Q00974, Q02334, Q03730, Q04083, Q09875, Q0D2K0, Q0V9U2, Q10000, Q29Q28, Q3E6T0, Q3SWX0, Q54V96, Q54ZG7, Q550W6, Q55FV8, Q5R7Q3, Q5T1Q4, Q6CR04, Q6FSF8, Q7RTP0, Q7TML3, Q8BGK5, Q8BHK1, Q8BLX4, Q8BMW7, Q8BZF2, Q8IXU6, Q8MXJ9, Q8N8Q9, Q8R1E7, Q8WY98, Q94EI9, Q968A5, Q9C8M1, Q9JJC8

Diamond homologs: O59785, Q0V9U2, Q5T1Q4, Q7TML3, Q8BGK5, Q8IXU6, Q550A6

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 66 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	5	17.9×	4e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

57 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	39
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1373 predictions. Top by Δscore:

Variant	Effect	Δscore
11:107802996:TTTA:T	donor_loss	1.0000
11:107802997:TTA:T	donor_loss	1.0000
11:107802998:TAC:T	donor_loss	1.0000
11:107802999:A:AG	donor_loss	1.0000
11:107803000:C:CA	donor_loss	1.0000
11:107803151:CAGGG:C	acceptor_gain	1.0000
11:107803153:GGG:G	acceptor_gain	1.0000
11:107803154:GG:G	acceptor_gain	1.0000
11:107803154:GGCTG:G	acceptor_loss	1.0000
11:107803156:C:A	acceptor_loss	1.0000
11:107803156:C:CC	acceptor_gain	1.0000
11:107803157:T:C	acceptor_loss	1.0000
11:107803158:G:C	acceptor_gain	1.0000
11:107803158:G:GC	acceptor_gain	1.0000
11:107805357:A:AC	donor_gain	1.0000
11:107805358:C:CC	donor_gain	1.0000
11:107805358:CAG:C	donor_gain	1.0000
11:107805368:C:CT	donor_gain	1.0000
11:107805400:T:TA	donor_gain	1.0000
11:107805423:G:C	donor_gain	1.0000
11:107806713:TCA:T	donor_loss	1.0000
11:107806714:CACC:C	donor_loss	1.0000
11:107806715:ACC:A	donor_loss	1.0000
11:107806716:C:T	donor_loss	1.0000
11:107806873:AAAG:A	acceptor_gain	1.0000
11:107806874:AAG:A	acceptor_gain	1.0000
11:107806875:AG:A	acceptor_gain	1.0000
11:107806875:AGC:A	acceptor_loss	1.0000
11:107806876:GC:G	acceptor_loss	1.0000
11:107806877:C:CA	acceptor_loss	1.0000

AlphaMissense

2425 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:107792757:C:T	G328E	0.998
11:107792758:C:G	G328R	0.998
11:107792758:C:T	G328R	0.998
11:107806771:C:G	G174R	0.998
11:107806778:A:C	C171W	0.998
11:107806780:A:G	C171R	0.998
11:107806875:A:G	L139P	0.998
11:107803034:G:C	S302R	0.997
11:107803034:G:T	S302R	0.997
11:107803036:T:G	S302R	0.997
11:107803048:C:G	A298P	0.997
11:107803053:A:G	L296P	0.997
11:107803062:A:G	L293P	0.997
11:107805370:A:C	S240R	0.997
11:107805370:A:T	S240R	0.997
11:107805372:T:G	S240R	0.997
11:107805393:C:G	G233R	0.997
11:107805497:C:T	G198D	0.997
11:107805498:C:A	G198C	0.997
11:107805498:C:G	G198R	0.997
11:107806770:C:T	G174D	0.997
11:107806779:C:T	C171Y	0.997
11:107806875:A:T	L139H	0.997
11:107815848:G:C	S76R	0.997
11:107815848:G:T	S76R	0.997
11:107815850:T:G	S76R	0.997
11:107815896:G:C	S60R	0.997
11:107815896:G:T	S60R	0.997
11:107815898:T:G	S60R	0.997
11:107792758:C:A	G328W	0.996

dbSNP variants (sampled 300 via entrez): RS1000052974 (11:107829030 C>A), RS1000085090 (11:107829371 A>G), RS1000105795 (11:107806467 T>A), RS1000117818 (11:107859811 C>A,G,T), RS1000147972 (11:107847585 T>C), RS1000171475 (11:107820782 C>A), RS1000196337 (11:107841166 T>A), RS1000226038 (11:107841344 C>A), RS1000311688 (11:107853734 A>G), RS1000327366 (11:107807015 G>A,C), RS1000390221 (11:107847109 G>A), RS1000415192 (11:107806192 T>C), RS1000459308 (11:107852913 C>A), RS1000473940 (11:107818650 T>A), RS1000488933 (11:107853199 T>C)

Disease associations

OMIM: gene MIM:620350 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST001877_15	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)	4.000000e-06

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — SLC35 family of nucleotide sugar transporters

CTD chemical–gene interactions

47 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, affects expression, affects cotreatment	9
trichostatin A	affects cotreatment, increases expression	3
Tretinoin	decreases expression, increases expression	3
Cyclosporine	decreases expression, increases expression	3
sodium arsenite	decreases expression, affects cotreatment, increases abundance, increases expression	2
Panobinostat	affects cotreatment, increases expression	2
Air Pollutants	decreases expression, increases abundance	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Smoke	decreases expression, increases abundance	2
triphenyl phosphate	affects expression	1
bisphenol A	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
cobaltous chloride	decreases expression	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
potassium chromate(VI)	increases expression	1
coumarin	decreases phosphorylation	1
deguelin	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
pyrimidifen	increases expression	1
ICG 001	increases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
bisphenol S	affects cotreatment, decreases expression	1
jinfukang	affects cotreatment, decreases expression	1
(+)-JQ1 compound	decreases expression	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Benzo(a)pyrene	increases expression	1
Cadmium	decreases expression	1
Caffeine	affects phosphorylation	1
Cisplatin	affects cotreatment, decreases expression	1

Cellosaurus cell lines

5 cell lines: 4 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B3HF	Abcam HEK293T SLC35F2 KO	Transformed cell line	Female
CVCL_D4D7	HCT116-SLC35F2-KO-c2	Cancer cell line	Male
CVCL_D4D8	HCT116-SLC35F2-KO-c3	Cancer cell line	Male
CVCL_TN27	HAP1 SLC35F2 (-) 1	Cancer cell line	Male
CVCL_TN28	HAP1 SLC35F2 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.